MDT-AP-0397
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- overall_survival_months
- 38.04
- os_event
- false
- age_years
- 17
- sex
- M
- new_clusters
- C6
- umap1_2d
- 4.343514587
- umap2_2d
- 7.202024976
- umap1_3d
- 3.236923031
- umap2_3d
- -1.392214611
- umap3_3d
- -4.345598066
- dataset
- Med-Taylor
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- OXIDATIVE_PHOSPHORYLATION+0.380
- PROTEIN_SECRETION+0.370
- DNA_REPAIR+0.350
- UNFOLDED_PROTEIN_RESPONSE+0.280
- HEME_METABOLISM+0.250
- ADIPOGENESIS+0.230
- PI3K_AKT_MTOR_SIGNALING+0.170
- BILE_ACID_METABOLISM+0.140
- PEROXISOME+0.120
- FATTY_ACID_METABOLISM+0.090
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.410
- ANGIOGENESIS-0.340
- ALLOGRAFT_REJECTION-0.330
- HEDGEHOG_SIGNALING-0.330
- E2F_TARGETS-0.310
- KRAS_SIGNALING_UP-0.310
- G2M_CHECKPOINT-0.300
- CHOLESTEROL_HOMEOSTASIS-0.290
- INFLAMMATORY_RESPONSE-0.270
- TNFA_SIGNALING_VIA_NFKB-0.260
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_DFWFBYSN | Med | Medulloblastoma | 0.844 |
| 2 | MDT-AP-1183 | Med | Medulloblastoma | 0.843 |
| 3 | MDT-AP-2588 | Med | Medulloblastoma | 0.826 |
| 4 | TCGA-A8-A099-01A-11R-A00Z-07 | — | B | 0.824 |
| 5 | MDT-AP-0026 | Med | Medulloblastoma | 0.824 |
| 6 | BS_3F4FQJMR | Supratentorial Ependymoma | — | 0.817 |
| 7 | 877f3bcc-97ea-4b0e-9f61-98a9eaedd952 | — | — | 0.809 |
| 8 | SRR6013584 | — | cohortA1 | 0.805 |
| 9 | SRR23303735 | — | — | 0.801 |
| 10 | TCGA-A8-A083-01A-21R-A00Z-07 | — | B | 0.796 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 14 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| OXIDATIVE_PHOSPHORYLATION | 0.380 | Remibrutinib | — uncovered |
| PROTEIN_SECRETION | 0.370 | Remibrutinib | — uncovered |
| DNA_REPAIR | 0.350 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.280 | Idelalisib | — uncovered |
| HEME_METABOLISM | 0.250 | Temsirolimus | — uncovered |
| ADIPOGENESIS | 0.230 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.170 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.140 | Inavolisib | — uncovered |
| PEROXISOME | 0.120 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.090 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.050 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.040 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.030 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.020 | Inavolisib | — uncovered |